Trial Information

Summary: Parkinson's Disease Dementia Study CENA713B2315

Novartis is conducting this clinical trial is to determine the long-term safety of ExelonŽ capsule and transdermal (through the skin) patch treatments in participants with Parkinson's disease dementia (PDD) over a period of 18 months (76 weeks). Study participants must have a reliable caregiver who will assist with keeping scheduled appointments, providing and/or applying medication, reporting any problems to the study center staff, and assessing the condition of the participant throughout the study.

Participants will be required to visit the study center approximately 10 times over 18 months (76 weeks). Participants assigned to the capsule will take the study medication ExelonŽ capsule twice a day. Participants assigned to transdermal patch will apply the ExelonŽ patch once per day which will be worn for 24 hours.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: December 3, 2008 at 3:33:54 PM